Clinical Trial Update: Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor [Phase 2]

View source ↗

Summary

Phase II study evaluating a myeloablative conditioning regimen of busulfan, melphalan, and fludarabine followed by an allogeneic hematopoietic stem cell transpl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• Busulfex (busulfan)
• Fludarabine (Fludarabine)
• Melphalan (Melphalan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2016-02-01